NCT07448610RecruitingPhase 4
ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Onasemnogene Abeparvovec: ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 26 Feb 2026
- Start date
- 27 Aug 2026
- Primary completion date
- 3 May 2032
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Spinal muscular atrophy
- NCT number
- NCT07448610
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 36
- From 27 Aug 2026 to the primary completion date, 3 May 2032
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
- Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
Other illness
- A participant will be excluded if any of the following conditions apply:
Other
- Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
- Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
- Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.
- Other protocol inclusion, exclusion criteria may apply.
Who the study is looking for
- A participant will be enrolled in STREAM only if all the following conditions are met:
- The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).
- He or she is ≥ 2 years of age on the day of the intrathecal injection.
- The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.
- One of the following functional categories applies at screening:
- independently ambulatory child/adolescent 2 - \<18 years; or
- independently ambulatory adult (≥ 18 years).
- non-ambulatory (includes walkers with assistance) adult \> 18 years with entry level RULM at baseline
- At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.
Age in the registry: 2 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Boston Childrens Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Ohio State University Medical Center Coordinator of this site? Confirm its status | Columbus | United States | Recruiting |
| Arkansas Children's Hospital Coordinator of this site? Confirm its status | Little Rock | United States | Recruiting |
| Columbia University Medical Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| Stanford Hospital Coordinator of this site? Confirm its status | Stanford | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.